Accurate assessment of ErbB2 in early breast cancer and metastases is clinically important because expression levels may correlate with tumor aggressiveness and disease-free survival, and may facilitate patient selection for ErbB2 specific therapies, dose adjustment, changes in treatment schedule, and monitoring of therapeutic response18. This evidence concerns the gene ERBB2 and breast carcinoma.